Formulation Development
iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd.
iBio, Inc. recently announced the commencement of a strategic commercial relationship with CC-Pharming Ltd. of Beijing, China for joint development of products and manufacturing facilities…
Codexis Doses First Subjects in Phase 1a Trial; Triggers Milestone
Codexis, Inc. recently announced it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered enzyme therapeutic being…
Eisai & Biogen Announce Positive Topline Results
Eisai Co., Ltd. and Biogen Inc. recently announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856…
Integrated Partnerships Paired With Innovative Approaches Are a Key to Success
As we come to learn more about the human body, the dynamics of the industry must react accordingly. A primary example of this is the fact that the dominating blockbuster drug model that was paramount in the industry until a couple of years ago is no longer valid……
Pfenex Receives Milestone From Merck
Pfenex Inc. recently announced the receipt of a milestone payment from Merck associated with the initiation of the first Phase 3 clinical study of (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.
Immatics Enters Strategic Partnership With Genmab
Immatics Biotechnologies GmbH recently announced it has entered into a research collaboration and license agreement with Genmab A/S to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications.
BioCanCell Announces Completion of $23-Million Financing
BioCanCell Ltd. recently announced it has completed a $22.9-million PIPE financing round. The financing was led by Shavit Capital, with investors from the US, Israel, and…
Immutep Submits IND Application With FDA
Immutep Limited recently announced it has submitted its Investigational New Drug (IND) application to the US FDA for eftilagimod alpha (efti or IMP321) in June…
Conatus Pharmaceuticals’ Pan-Caspase Inhibitor Emricasan Improves Survival & Portal Hypertension
Conatus Pharmaceuticals Inc. recently announced the publication of results from preclinical studies of its pan-caspase inhibitor emricasan, demonstrating improvements in portal hypertension (elevated blood pressure…
Catalent Signs Agreement to Acquire Juniper Pharmaceuticals
Catalent, Inc. recently announced it has agreed to acquire Juniper Pharmaceuticals, Inc., including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing…
BASi & Seventh Wave Laboratories Combine Operations to Provide Broader Solutions & Greater Scientific Expertise to Clients
Bioanalytical Systems, Inc. and Seventh Wave Laboratories, LLC, recently announced they have signed an asset purchase agreement (APA) joining operations to provide broader solutions and…
ASLAN Pharmaceuticals Submits Clinical Trial Authorization Application
ASLAN Pharmaceuticals recently announced the submission of a clinical trial authorization application with the Singapore Health Sciences Authority (HSA) to initiate a Phase 1 trial…
Biologic Excipients Market Expected to be Valued at $1.7 Billion by End of 2028
Future Market Insights (FMI) delivers key insights on the global biologic excipients market in its upcoming report titled Biologic Excipients Market: Global Industry Analysis 2013–2017 and Opportunity Assessment…
Lonza Launches New Bioscience Website
Lonza Bioscience is inviting visitors to explore its new dedicated website: bioscience.lonza.com.
CrownBio Enters Partnership With Pierre Fabre to Accelerate Discovery & Development of Immuno-Oncology Agents
Crown Bioscience recently announced it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.…
Atossa Genetics Completes All Dosing & Clinical Visits in its Study of Topical Endoxifen
Atossa Genetics Inc. recently announced it has completed dosing and clinical visits in its Phase 1 study of its proprietary topical Endoxifen in men. “We…
Celyad Doses First AML Patient at Final Dose Level in CYAD-01 THINK Trial & Begins Dosing First Patient With Second Cycle of Therapy
Celyad recently announced the first Acute Myeloid Leukemia (AML) patient was dosed with the first injections at the third and final dose level of CYAD-01…
Allena Pharmaceuticals Completes Animal Proof-of-Concept Study
Allena Pharmaceuticals, Inc. recently announced the completion of an animal proof-of-concept study supporting the selection of ALLN-346 as its lead product candidate for the treatment…
7 Hills Pharma Launches With $2-Million SBIR Grant & $4 Million in Seed Capital
7 Hills Pharma recently announced it has been awarded a $2-million Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH) titled…
Evonik Expands North American Contract Development & Manufacturing Capabilities for Advanced Injectables
Evonik recently announced a €35 million expansion of its contract development and manufacturing (CDMO) capabilities in North America to meet growing demand for controlled release injectable formulations. The expansion of the U.S. and Canadian facilities, which includes the installation of a new filling line, production facilities and analytical labs, will create more than 50 jobs.
